Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. BB's Stock Haven Message Board

ITNS in some 0017 on CBD news Itonis, Inc. announc

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 38674
(Total Views: 133)
Posted On: 09/26/2018 2:18:25 PM
Posted By: i_like_bb_stock
ITNS in some 0017 on CBD news Itonis, Inc. announces Emesyl Plus homeopathic nasal spray containing Premium Hemp Oil GlobeNewswire "Press Releases"
LAGUNA HILLS, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Itonis, Inc. (OTC PINKSHEETS: ITNS)

Itonis, Inc. is pleased to announce Emesyl Plus, a new revolutionary homeopathic nasal spray containing Premium Hemp Oil derived from hemp seeds from Cannabis sativa plants. The product is immediately available for sale on Amazon, and can be found here: https://www.amazon.com/dp/B07H2Z9BHS.
Emesyl Plus is used to help fortify your mind and body, target moderate changes in health, and to strengthen a foundation of overall wellness. As Emesyl Plus includes the Emesyl anti-nausea formula as well, it also offers all the same benefits as Emesyl, the companys flagship product used to treat nausea and nausea-like symptoms.
Emesyl Plus is manufactured by National Homeopathic Labs , also the manufacturer of Emesyl. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements for over 25 years.
Itonis is also pleased to announce that Emesyl Plus carries a two year expiration from the date of manufacture. The product is currently in the process of extended Stability testing for three year expiration, and an announcement will be made as soon as the additional Stability testing requirements are complete.
Additional information about Emesyl Plus can be found on DailyMed, operated by theU.S. National Library of Medicine (NLM): https://dailymed.nlm.nih.gov/dailymed/drugInf...f516e867f2.
We are very excited with the launch of Emesyl Plus, and look forward to strong product demand in helping others to strengthen a foundation of overall wellness, said Steve Pidliskey , Itonis Vice President. We believe Emesyl Plus will be a knockout winner in the marketplace.
Meanwhile, our original Emesyl Nausea Relief nasal spray continues to be sold by a reseller at Amazon.com (https://www.amazon.com/Itonis-Inc-Emesyl-Nausea-Relief/dp/B00U20H3KI/ref=sr_1_1_a_it?ie=UTF8&qid=1537974790&sr=8-1&keywords=Itonis%2C+Inc ) and at Walmart.com (https://www.walmart.com/ip/Emesyl-Nausea-Relief/792523063). It is also available directly from Itonis at https://www.emesyl.com/.
About Itonis, Inc.
Located in Laguna Hills, California , and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. Please visit www.itonisholdings.com for additional information.
About National Homeopathic Labs .
Located in Las Vegas, Nevada , National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that specializes in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission . The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact: Itonis, Inc. Office@itonisholdings.com

Itonis, Inc. Office@itonisholdings.com




Source: Itonis, Inc.


(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us